Evidence map›Paper›PMID 32020528›Full record

ArticleLa Radiologia medica2020

Application of the ESR iGuide clinical decision support system to the imaging pathway of patients with hepatocellular carcinoma and cholangiocarcinoma: preliminary findings.

Michela Gabelloni, Matteo Di Nasso, Riccardo Morganti, Lorenzo Faggioni, Gianluca Masi, Alfredo Falcone, Emanuele Neri

Abstract read
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Exploring Radiologists' Burnout in the COVID-19 Era: A Narrative Review.International journal of environmental research and public health · 2023
    Review
  12. Radiomics in Lung Metastases: A Systematic Review.Journal of personalized medicine · 2023
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Michela GabelloniDiagnostic and Interventional Radiology, Department of Translational Research, University of Pisa, Via Roma, 67, 56126, Pisa, Italy. mgabelloni@sirm.org.ORCID http://orcid.org/0000-0002-6668-499X
Matteo Di NassoDiagnostic and Interventional Radiology, Department of Translational Research, University of Pisa, Via Roma, 67, 56126, Pisa, Italy.
Riccardo MorgantiDepartment of Clinical and Experimental Medicine, Section of Statistics, University of Pisa, Via Roma, 67, 56126, Pisa, Italy.
Lorenzo FaggioniDiagnostic and Interventional Radiology, Department of Translational Research, University of Pisa, Via Roma, 67, 56126, Pisa, Italy.
Gianluca MasiDepartment of Oncology, University Hospital of Pisa, Via Roma, 67, 56126, Pisa, Italy.
Alfredo FalconeDepartment of Oncology, University Hospital of Pisa, Via Roma, 67, 56126, Pisa, Italy.
Emanuele NeriDiagnostic and Interventional Radiology, Department of Translational Research, University of Pisa, Via Roma, 67, 56126, Pisa, Italy.
University of Pisa · ITAzienda Ospedaliera Universitaria Pisana · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOur purpose was to assess the performance of ESR iGuide for assisting the selection of the most appropriate imaging tests based on clinical signs and symptoms in patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC).

methodsWe retrospectively reviewed the medical records of 113 patients with a final diagnosis of HCC or CC. Data from a cohort of 40 patients with a reported clinical history suggestive for either disease, who had undergone at least their first imaging test related to their condition at the same Institution, were entered into ESR iGuide. The appropriateness level of the diagnostic tests suggested by ESR iGuide was compared with that of the tests actually performed.

resultsAll patients underwent several imaging examinations, ranging from a minimum of 1 to a maximum of 4, for a total of 98 diagnostic procedures. Of these, 79.6% (78/98) were considered "usually appropriate" by ESR iGuide, 11.2% (11/98) were designated as "may be appropriate", and 9.2% (9/98) were not even suggested. Given a total estimated cost of €14,016 for the 98 examinations performed within the regional (BLINDED) healthcare system, the usage of ESR iGuide would have allowed saving €3033 (21.6%) due to inappropriate testing.

conclusionsIn patients with HCC or CC, ESR iGuide can be effective in guiding the selection of the appropriate imaging examinations and cutting costs due to inappropriate testing.

Indexed as

Decision Support Systems, ClinicalBile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaGuideline AdherenceHumansLiver NeoplasmsPractice Guidelines as TopicRetrospective StudiesAppropriateness criteriaCholangiocarcinomaClinical decision support systemsDiagnostic imagingHepatocellular carcinoma

Identifiers

PMID32020528
OpenAlexW3004568692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.